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Abstract: A plethora of cellular functions are controlled by calcium signals, that are greatly 
coordinated by calcium release from intracellular stores, the principal component of which is the 
sarco/endooplasmic reticulum (S/ER). In 1997 it was generally accepted that activation of various G 
protein-coupled receptors facilitated inositol-1,4,5-trisphosphate (IP3) production, activation of IP3 
receptors and thus calcium release from S/ER. Adding to this, it was evident that S/ER resident 
ryanodine receptors (RyRs) could support two opposing cellular functions by delivering either highly 
localised calcium signals, such as calcium sparks, or by carrying propagating, global calcium waves. 
Coincidentally, it was reported that RyRs in mammalian cardiac myocytes might be regulated by a 
novel calcium mobilising messenger, cyclic adenosine diphosphate-ribose (cADPR), that had recently 
been discovered by HC Lee in sea urchin eggs. A reputedly selective and competitive cADPR 
antagonist, 8-bromo-cADPR, had been developed and was made available to us. We used 
8-bromo-cADPR to further explore our observation that S/ER calcium release via RyRs could mediate 
two opposing functions, namely pulmonary artery dilation and constriction, in a manner seemingly 
independent of IP3Rs or calcium influx pathways. Importantly, the work of others had shown that, 
unlike skeletal and cardiac muscles, smooth muscles might express all three RyR subtypes. If this were 
the case in our experimental system and cADPR played a role, then 8-bromo-cADPR would surely 
block one of the opposing RyR-dependent functions identified, or the other, but certainly not both. 
The latter seemingly implausible scenario was confirmed. How could this be, do cells hold multiple, 
segregated SR stores that incorporate different RyR subtypes in receipt of spatially segregated signals 
carried by cADPR? The pharmacological profile of 8-bromo-cADPR action supported not only this, 
but also indicated that intracellular calcium signals were delivered across intracellular junctions 
formed by the S/ER. Not just one, at least two. This article retraces the steps along this journey, from 
the curious pharmacological profile of 8-bromo-cADPR to the discovery of the cell-wide web, a 
diverse network of cytoplasmic nanocourses demarcated by S/ER nanojunctions, which direct site-
specific calcium flux and may thus coordinate the full panoply of cellular processes. 
Keywords: 8-bromo-cADPR; cADPR; calcium; hypoxic pulmonary vasoconstriction; sarcoplasmic 
reticulum; KV7; ryanodine receptor; two pore channel 2; arterial smooth muscle; nanojunction; 
nanospace; nanocourse; nucleus; nuclear invagination 
 
1. Introduction 
Cells select for one or a combination of distinct functions through calcium signalling. Therefore, 
stimuli must induce different calcium signals to select for one or other of a variety of specific cellular 
processes, such as cell activation, inhibition and proliferation, which additionally requires changes in 
gene expression [1]. A variety of highly specialised, intracellular ion channels evolved for this purpose 
[2,3]. However, despite the extraordinarily detailed mapping of the temporal characteristics of both 
unitary and macroscopic calcium signals across a variety of cell types [4–10], how cells deliver the 
diverse range of site- and function-specific calcium signals necessary to coordinate the full panoply of 
cellular processes remains enigmatic [11,12]. 
The primary intracellular calcium store is the sarco/endoplasmic reticulum (S/ER), which forms a 
contiguous organelle from its origin at the outer nuclear membrane to the periphery of all cells [13]. 
Calcium signals with clear diversities of form and function are delivered via the S/ER, in a manner that 
meets the specific functional requirements of a given cell type [6,7,10,12,14]. Irrespective of cell type the 
current consensus is that within a wide, open cytoplasm highly localised calcium signals (e.g. calcium 
sparks) direct region-specific functions, while propagating global calcium signals coordinate primary 
cell-specific functions (e.g. muscle contraction, secretion). Adding to this, adjustments to gene 
expression are presumed to be governed by variations in the spatiotemporal patterns of global calcium 
transients that gain unrestricted entry to the nucleoplasm across the nuclear envelope and its 
invaginations [15–19]. 
This review will retrace the steps in the development and testing of a novel hypothesis on the 
mechanism of intracellular calcium signalling, that was first prompted by the very peculiar 
pharmacology of 8-bromo-cyclic adenosine diphosphate-ribose (8-bromo-cADPR; Figure 1) [20]. 
Importantly, 8-bromo-cADPR had been proposed to be a competitive antagonist of cyclic adenosine 
diphosphate-ribose (cADPR), a novel calcium mobilising pyridine nucleotide [21]. The 
pharmacological profile of 8-bromo-cADPR of which I speak was at first sight surprising, but then 
became curiouser, and curiouser still. There seemed to be one explanation for outcomes and one 
explanation only, that different calcium signals must be delivered by different SR compartments, into 
functionally distinct cytoplasmic spaces, somehow demarcated by junctions formed by the SR [11,22–
25]. Our further studies ultimately led to the discovery of the cell-wide web, a network of cytoplasmic 
nanocourses demarcated by S/ER, which direct calcium signals in a manner that may be sufficient to 
allow for stimulus-specified coordination of the full panoply of cellular processes. 
 
Figure 1. 8-Bromo-cyclic ADP-ribose. 
However, the path to the cell-wide web did not begin with considerations on calcium signalling 
per se, but with the discovery of a novel potassium current in acutely isolated pulmonary arterial 
smooth muscle cells. Therefore, in order to understand the “logic” of each step along this experimental 
road, the story must begin here. 
2. A Tale of Two Channels and Perhaps a Few Dollars More 
During 1994 I was tasked with characterising potassium channels in porcine pulmonary arterial 
myocytes, with the aim of determining whether, as postulated, exposure to hypoxia during the 
perinatal period altered normal developmental changes in potassium currents (kinetics and 
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pharmacology) and in doing so contributed to the development of persistent pulmonary hypertension 
of the newborn. It is satisfying, with hindsight, to report that this hypothesis was confirmed [26], which 
deserves mention because these studies were riddled with periodic delays and lengthy periods of out 
and out failure. That said, these delays allowed me the freedom for pure unadulterated exploration of 
an unknown. 
It had been proposed that the resting membrane potential of pulmonary arterial myocytes was 
determined not by the large conductance voltage- and calcium-activated potassium current (BKCa; 
KCa1.1 to the youth of today) but by a delayed rectifier potassium current (IKV), the primary component 
of which we now know is carried by KV1.5 [27–30]. At the time pharmacological tools were limited and 
poorly selective, while molecular interventions had yet to come of age. Therefore, I considered other 
ways in which I might test whether it was indeed the delayed rectifier that set the resting membrane 
potential of pulmonary arterial myocytes. Prolonged depolarisation was thought to evoke voltage- and 
time-dependent inactivation of all known KV currents. Therefore, I designed a protocol that would 
remove these potassium channels through voltage-dependent inactivation. I held cells under voltage-
clamp for 1–2 h at 0 mV and then switched immediately to current clamp (I = 0), leaving each cell to 
report its residual resting membrane potential (experimental protocol reported in [31]). In those few 
experiments that lasted the course, I was astonished to find that the resting membrane potential 
remained the same as it was before the inactivation protocol had been engaged, not altered by even a 
single mV. This led to the discovery of a novel low threshold voltage-gated, low conductance potassium 
current that was activate at the resting membrane potential of pulmonary arterial myocytes 
(approximately −60 mV), which I named IKN because it did not inactivate [32]. By contrast, the threshold 
for activation of IKV/KV1.5 is −40 mV, +20 mV above the resting membrane potential recorded in acutely 
isolated cells with a seal resistance ³10 GW [32], or for that matter in smooth muscle cells in-situ in an 
intact artery [33]. The characteristics of IKN were so strikingly similar to the neuronal M-current [32] 
that subsequent studies of others inevitably demonstrated, as predicted [32], that they were both 
conferred by the same potassium channel type, namely KV7 [34,35]. At this point I was asked to involve 
a fellow post-doctoral researcher, Oleg Osipenko, in my further investigations on IKN, which confirmed 
my findings, and furthermore suggested that IKN might be inhibited during hypoxia [31]. It was 
therefore proposed that inhibition of IKN rather than IKV [27–29,36] was most critical to the induction 
of hypoxic pulmonary vasoconstriction (HPV), a reflex response of pulmonary arteries to falls in airway 
and alveolar oxygen availability [37]. It was made clear to me that the effects of hypoxia on IKN were 
not for me to test, and to this day I have not done so. Rather than any long-term compliance on my part, 
this was due to a twist in the tale that I was presented with on setting up my own laboratory to further 
my independent studies on IKN. 
3. KN or Not KN that Was the Question 
HPV is a local response mediated by mechanisms intrinsic to the smooth muscles and endothelia 
of the pulmonary blood vessels, that helps optimise ventilation-perfusion matching by diverting blood 
flow through the path of least resistance, from oxygen-deprived to oxygen-rich areas of the lung; by 
contrast most aspects of the systemic vasculature dilate during hypoxia to ensure that oxygen 
availability meets the needs of the organs and tissues thus supplied [38]. HPV is triggered by airway 
and alveolar hypoxia [37,39], rather than by vascular hypoxaemia [40], through the constriction of pre-
capillary resistance arteries within the pulmonary circulation, in a manner coordinated by signalling 
pathways that are intrinsic to their smooth muscles and endothelial cells [41–44], independently of 
blood-borne mediators or the autonomic nervous system [45,46]. The initiation phase of acute HPV is 
primarily driven by smooth muscle constriction [41], with a threshold PO2 ≈ 80 mmHg [24]. The cell-
specific expression of atypical nuclear encoded subunits of the mitochondrial electron transport chain, 
such as COX4I2, may confer the acute sensitivity of these oxygen-sensing cells to physiological hypoxia 
[47,48], while increased expression, relative to systemic arteries, and activation of the AMP-activated 
protein kinase appears critical to induction of HPV downstream of mitochondria [49,50], including 
therein direct phosphorylation and inhibition of KV1.5 channels that underpin the aforementioned IKV 
[50,51]. That is as it stands now, but we knew little of this back then. 
When evoked in isolated pulmonary arterial rings by switching from normoxic to hypoxic gas 
mixtures, HPV presents as a biphasic response (Figure 2), with an initial transient constriction (phase 
1) being followed by a slow tonic constriction (phase 2) [41,52–54]. Both phases of constriction are 
superimposed on each other; that is to say, they are discrete events that are initiated concomitantly 
upon exposure of pulmonary arteries to hypoxia. The initial transient constriction peaks within 5–10 
min of the onset of hypoxia, whilst the underlying, tonic constriction peaks after a further 30–40 min of 
hypoxia. The gradual amplification of phase 2 is driven by the release of an endothelium-derived 
vasoconstrictor [43,55,56], the identity of which is still open to question. Therefore, after the 
endothelium is removed the phase 1 constriction declines to a maintained plateau [41]. 
 
Figure 2. Schematic diagram that describes the two phases of hypoxic pulmonary vasoconstriction 
(HPV) triggered upon exposure of an isolated pulmonary artery ring to hypoxia. Phase 1 is driven by 
the smooth muscle (black). Phase 2 is driven by the smooth muscle (grey) and amplified through an 
endothelium-dependent mechanism (white). 
The prevailing hypothesis back then was, and still now remains so in the eyes of some, that HPV 
is triggered by the inhibition of voltage-gated potassium channels, consequent membrane 
depolarisation and voltage-gated calcium influx [27–29,36,47,57,58]. 
In 1996 I set about designing a series of experiments that would confirm the preeminent role of 
potassium channels in HPV, and IKN in particular, using experimental protocols that extended my work 
on acutely isolated smooth muscles to isolated pulmonary arterial rings and the whole rat lung in-situ, 
with the kind support of Dr Piers Nye. In these investigations I was ably assisted by my first PhD 
student, Michelle Dipp, who consistently obtained acute and robust HPV using isolated pulmonary 
artery rings without the need for the application of pre-tone by way of an applied vasoconstrictor; a 
common practice in other labs, perhaps to overcome less nimble dissection, and/or the use of 
anaesthetics during sacrifice, such as pentobarbitone (see also [59]). 
My first priority was to complete the most obvious and critical experiment the literature appeared 
to lack. In my mind this was a sure-fire bet, IKN would win the day. We (Michelle) would remove 
extracellular calcium from the medium using the calcium chelator EGTA, and balance the loss of this 
divalent cation by addition of equimolar quantities of magnesium. Constriction of pulmonary artery 
rings during hypoxia would be abolished, there could be no doubt about that, and then we would move 
on. To be doubly sure, I suggested we control for any input from the endothelium by removing it from 
paired artery rings. Michelle and I met at the end of the first week to discuss her preliminary findings. 
HPV is biphasic
To my astonishment, she informed me that there was only a very little change in the response to 
hypoxia of the endothelium-denuded artery [41]. I think I said something along the lines of, “What, 
show me the records!”. She did and sure enough HPV (phases 1 and 2) was at best partially inhibited, 
whether one considered each individual experiment, or the average. Michelle replied “Is that not what 
you expected?”; she was not surprised at all as she had simply been asked to tell me what she found. 
Moreover, the constriction induced through membrane depolaristion in response to high extracellular 
potassium (80 mM; negative control) was abolished as expected, confirming the most unexpected of 
outcomes, that neither potassium channel inhibition or voltage-gated calcium influx was a pre-requisite 
for acute HPV. Michelle offered me solace by revealing records from intact arteries, where the 
endothelium-dependent component of HPV had been attenuated, suggesting that calcium influx into 
the endothelium was required for vasoconstrictor release. This did not help my mindset at the time, as 
I was so focused on the mechanism at play within the smooth muscles. However, intrinsic HPV was 
and, as attested to by removal of the endothelium, it was most likely triggered by calcium release from 
intracellular stores within pulmonary arterial myocytes. This was confirmed by pre-incubation of 
pulmonary arteries with ryanodine and caffeine, which blocked calcium release from the SR via RyRs 
without depleting the SR calcium store. Phase 1 and phase 2 of HPV were duly abolished, but this 
intervention did not affect constriction by high potassium [41]. Perhaps most astonishingly, when 
considered alongside the fact that HPV could be induced in the absence of extracellular calcium, this 
outcome indicated that calcium released from the SR was somehow locked inside the cell, because HPV 
was sustained for a long time in calcium-free media, longer than the limits of any test we carried out 
(i.e. hours). It should however be noted that the maintained phase of constriction of pulmonary artery 
rings without endothelium was attenuated by up to 50% in calcium-free medium, consistent with the 
view that HPV is supported by consequent activation of a store-depletion-activated calcium entry 
pathway(s) [60]. 
Several investigations had previously suggested that HPV may be facilitated in part by calcium 
release from SR stores [52,61–64], but none had so clearly demonstrated that this was initiated 
independent voltage-gated calcium influx and endothelium-derived vasoconstrictors. Hence general 
acceptance of the dominant hypothesis of the time, that HPV was triggered by KV channel inhibition 
and consequent voltage-gated calcium influx [27–29,36,47,57,58], which had now been debunked, from 
my perspective at least. 
4. Two for Tea: Another Awkward Moment in Time 
My first post-doctoral researcher, Francois Boittin, joined us the following year. I set Francois a 
parallel study, to examine the cellular mechanism by which a b-adrenoceptor agonist, isoprenaline, 
mediated relaxation of pulmonary arterial smooth muscles. It turned out that while Francois was an 
excellent electrophysiologist, he was not adept at small or large artery dissection; when supplied with 
Francois’ arteries, Michelle pointed out that they were almost dead on arrival, “Mark, they may contract 
to potassium, just, but not hypoxia!”. In short, this study became a team effort, naturally. 
Like many other Gs coupled receptors, b-adrenoceptors had been shown to activate adenylyl 
cyclase, increase cyclic adenosine monophosphate (cAMP) levels and mediate vasodilation in a protein 
kinase A (PKA)-dependent manner. In a variety of smooth muscles PKA appeared to facilitate 
relaxation by: (1) increasing SR filling through SERCA pump acceleration, consequent to 
PKA-dependent phosphorylation of the SERCA inhibitory protein phospholamban, which promotes 
its dissociation from SERCA [65,66]; (2) increasing calcium spark frequency through peripheral RyRs 
due to increased SR calcium load [67,68]; (3) facilitating activation of plasmalemma resident voltage- 
and calcium-activated large conductance potassium channels (BKCa, KCa1.1) and thus membrane 
hyperpolarisation, directly through BKCa channel phosphorylation [69] and indirectly through 
increased calcium spark frequency from regions of the SR proximal to the plasmalemma [8,70]. 
Thereafter, voltage-gated calcium entry would be reduced, and calcium removal from the cell 
facilitated via sodium/calcium exchangers and/or P-type calcium ATPase pumps located in the 
plasmalemma [71]. What had intrigued me was a report that hypoxia attenuated this response in 
pulmonary arteries, as it seemed plausible that inhibition of this pathway to vasodilation might 
facilitate HPV by removing opposition to depolarisation-evoked calcium influx consequent to the 
inhibition of IKN and IKV. Consistent with previous studies, we found that b-adrenoceptor activation 
and membrane permeable cAMP analogues did indeed hyperpolarise pulmonary arterial myocytes by 
activating iberiotoxin-sensitive BKCa channels, and in a PKA-dependent manner. Critically, 
vasodilation by b-adrenoceptor activation was attenuated by ~60% by blocking RyRs with ryanodine, 
~60% following depletion of SR calcium stores through SERCA inhibition using cyclopiazonic acid 
(Figure 3), and by ~90% following direct block of BKCa channels with iberiotoxin [25]. In short, 
vasodilation was indeed facilitated by SR calcium release through RyRs and consequent activation of 
BKCa channels. 
 
Figure 3. Example records show that the cADPR antagonist 8-bromo-cADPR (top left), ryanodine 
receptor block with ryanodine (bottom left) and depletion of sarcoplasmic reticulum calcium stores with 
cyclopiazonic acid (CPA; top right) attenuates (~60%) pulmonary artery dilation induced by 
Isoprenaline. Blocking BKCa channels with iberiotoxin delivers ~90% attenuation (bottom right). 
5. Hey Hey CPA Say: Had Me a Store but One Ran Away 
We had confirmed that two opposing responses, vasodilation and vasoconstriction, were 
mediated by calcium release from the SR through RyRs. Moreover cAMP-dependent vasodilation was 
facilitated by calcium release from a cyclopiazonic acid-sensitive SR store. There is only one contiguous 
unit of SR [13,72] and cyclopiazonic acid is a non-selective SERCA inhibitor [73,74], right? So, HPV 
would be even more sensitive to pre-incubation with cyclopiazonic acid, particularly when the 
endothelium is removed from the arteries. Stands to sense, under these conditions we had shown HPV 
to be entirely dependent on SR calcium release through RyRs. Right question, wrong answer, again! 
Cyclopiazonic acid abolished the first transient phase of HPV, but left the sustained phase 2 
constriction unaltered, the second phase reaching a steady plateau much like control, that was 
sustained for hours [24]. My response to Michelle was, “it doesn’t make sense, do it again”. Same thing 
happened, again and again (Figure 4). Adding to this, in case it has escaped your attention, our studies 
on vasodilation had relied upon pre-constriction of pulmonary arteries with prostaglandin F-2a, which 
we had previously confirmed to induce vasoconstriction, at least in part, by mobilising intracellular 

















8-bromo-cADPR attenuates isoprenaline-induced vasodilation
Could there be two discrete SR stores after all, one sensitive and one insensitive to cyclopiazonic 
acid? There were data in the literature to support such a position [75–79], and the earliest of these 
studies was on pulmonary arteries; albeit from the guinea-pig, which exhibits markedly attenuated 
HPV due to adaptation to life at altitude [80]. Moreover, much like previous studies on acutely isolated 
airway smooth muscles [81,82], we had found that in acutely isolated pulmonary arterial myocytes 
isoprenaline-induced signalling pathways preferentially raised intracellular calcium concentration at 
the perimeter of these cells, proximal to the plasmalemma [25]. 
 
Figure 4. Example records show that pre-incubation of pulmonary artery rings with 8-bromo-cADPR, a 
cADPR antagonist, blocked phase 2, but not phase 1, of HPV (upper panels). By contrast, depletion of 
sarcoplasmic reticulum calcium stores with cyclopiazonic acid (CPA) blocked phase 1, but not phase 2, 
of HPV (lower panels). 
6. 8-Bromo-cADPR and the Magical Mystery Tour Takes Off 
During 1997 I became aware of a certain b-NAD+ metabolite, cADPR, from a poster I read while 
wandering the corridors at Oxford. Between 1989 and 1991, Hong-Cheung Lee and co-workers had 
published their seminal studies on sea urchin eggs that led to the discovery of cADPR, and the enzyme 
activities for its synthesis and metabolism [21,83,84]. More importantly still, from my perspective at the 
time, they had also identified the most likely downstream target of cADPR, namely sea urchin RyRs 
[85]. Albeit very slowly, data had thereafter begun to emerge in support of a similar role for cADPR in 
mammalian cells [84,86–90]. A competitive and membrane permeable cADPR antagonist had also been 
developed and was made available to me, namely 8-bromo-cADPR (Figure 1) [20]. Given its likely role 
in regulating RyRs, it seemed more than plausible that cADPR might facilitate HPV or pulmonary 
artery dilation, but it couldn’t be involved in both now, could it? 
To break the suspense, 8-bromo-cADPR did indeed block isoprenaline-induced dilation of 
pulmonary arteries (Figure 3) [25], and also inhibited HPV in isolated pulmonary artery rings and in 
the rat lung in-situ (Figure 4) [24]. However, with respect to the latter its effects were quite different 
from the picture painted by the combinatorial action of ryanodine and caffeine, which blocked HPV in 
its entirety [41]. 
In arteries with and without endothelium, pre-incubation with 8-bromo-cADPR had no effect on 
phase 1 of HPV, which was blocked by pre-incubation with ryanodine and caffeine. But, somewhat 
counterintuitively, it abolished the sustained phase 2 constriction whether the endothelium was present 









8-bromo-cADPR identifies two components of SR calcium release during HPV
or not (Figure 4) [24]. Once again, I told Michelle that the experimental outcomes did not make any 
sense, and that she would have to repeat this experiment again, but this time in a variety of different 
ways. We’ll come back to that later, suffice to say for now that 8-bromo-cADPR blocked phase 2, but 
not phase 1 of HPV. This was in stark contrast to cyclopiazonic acid, which had taken out the phase 1 
constriction but left the sustained phase 2 constriction unaltered (Figure 4) [24]. In short, with respect 
to HPV the effects of inhibiting RyR activation with 8-bromo-cADPR and blocking SR calcium uptake 
with cyclopiazonic acid were not simply opposite from each other, but contrary. These findings 
appeared incompatible with the view that the SR operated as one contiguous unit [13]. Yet the effects 
of pre-incubation with ryanodine and caffeine were consistent with a contiguous SR, given that HPV 
and constriction by prostaglandin F-2a were blocked in their entirety under these conditions [41]. Recall 
again, that for studies on cADPR-dependent vasodilation we pre-constricted pulmonary arteries with 
prostaglandin F-2a, which induced vasoconstriction, in part, by mobilising SR calcium from a 
cyclopiazonic-insensitive store [41]. 
Accepting all of the above to be bona fide, it was evident that if the effects of 8-bromo-cADPR on 
HPV were indeed due to it blocking the action of cADPR, then cADPR must be necessary for SR calcium 
release to occur during the initiation and maintenance of phase 2 of HPV, even though it was not 
required in the context of phase 1. For this to be the case hypoxia must somehow increase cADPR levels 
in pulmonary arterial smooth muscles. This was confirmed by parallel analysis of the synthesis and 
metabolism of cADPR within homogenates of pulmonary arterial smooth muscles, with the support of 
the Galione laboratory through the redeployment of Heather Wilson and Justyn Thomas; a favour to 
be repaid, and some, a few years later. Surprisingly, these endogenous enzyme activities were greater 
in smooth muscles from pulmonary arteries when compared to that from systemic arteries. This was a 
significant finding because it provided, in some small part, the necessary degree of pulmonary 
selectivity that would be required of any mediator of HPV. Moreover, the level of ADP-ribosyl cyclase 
and hydrolase activities were inversely related to pulmonary artery diameter [91]. Accordingly, 
analysis of smooth muscle cADPR levels revealed marked increases in its accumulation during hypoxia 
(16–21 mm Hg; 1 h). Twofold in second-order branches of the pulmonary arterial tree, and tenfold in 
third-order branches. Thus, much like the magnitude of HPV and the distribution of the enzyme 
activities for cADPR synthesis, hypoxia-evoked increases in cADPR content were inversely related to 
pulmonary artery diameter [91]. 
Our further studies provided evidence that increased b-NADH formation under hypoxic 
conditions may facilitate cADPR formation from b-NAD+, by either augmenting ADP-ribosyl cyclase 
and/or inhibiting cADPR hydrolase activities [91]. Adding to this, later experiments suggested that 
cADPR accumulation and/or RyR activation by cADPR requires prior activation of AMPK, consequent 
to inhibition of mitochondrial oxidative phosphorylation during hypoxia [49,50]. Over and above this, 
the precise mechanism by which hypoxia promotes cADPR accumulation in pulmonary arterial smooth 
muscles remains to be confirmed. 
7. 8-Bromo-cADPR Action: on the Face of it All or Nothing 
The aforementioned studies led us to perhaps the most unexpected and surprising observation 
thus far. As mentioned above, when presented with the records showing that 8-bromo-cADPR blocked 
phase 2, but not phase 1, of HPV, I told Michelle that these experimental outcomes did not make any 
sense, and suggested she repeat this experiment again, and in a variety of different ways. This was 
Pharmacology we were dealing with, not Physiology, and 8-bromo-cADPR was purportedly a 
competitive antagonist. Therefore, to understand its mechanism of action on pulmonary arteries in 
necessary detail, a concentration-response curve would be required, with and without the endothelium. 
My general viewpoint was that the differential effects on phase 1 and phase 2 of HPV must in some 
way be related to the concentration applied. Either we were dealing with differences in affinity between 
different RyR subtypes, or the pharmacokinetics of 8-bromo-cADPR led to difficulties in accessing one 
cellular compartment relative to another. 
As ever Michelle received the plan with a smile, and promptly got on with it. We reconvened to 
discuss her findings sooner than I had expected, within one week. She presented me with yet another 
imponderable. When arteries were pre-incubated with 8-bromo-cADPR at 1µM there was no effect on 
either phase 1 or phase 2 of HPV, but at 3 µM phase 2 was abolished (Figure 5). All-or-none block with 
a competitive antagonist? Quite mad! I began to doubt the compounds legitimacy, as not even 
phenoxybenzamine would act like this over the time period given for pre-incubation; for the 
uninitiated, phenoxybenzamine binds to its protein targets (e.g. alpha adrenoceptors) covalently, 
irreversibly and in a time-dependent manner. A competitive antagonist should block a response driven 
by agonist-receptor coupling in a concentration-dependent manner, with complete block achieved 1–2 
orders of magnitude above the threshold concentration at which partial inhibition of this response is 
first seen. 
Could we reveal concentration-dependency of 8-bromo-cADPR in another way? I recalled the all-
or-none, quantal activation of units of nicotinic acetylcholine receptors by acetylcholine at the 
neuromuscular junction, and the demonstration that competitive antagonists of nicotinic acetylcholine 
receptors could block neuromuscular transmission in an all-or-none manner when applied prior to 
induction of a single “spike” of contraction, yet deliver concentration-dependent inhibition of 
contraction once tetanus (sustained contraction) had been induced [92–96]. The all-or-none block of 
neuromuscular transmission occurred when the activation of a “critical mass” (~45%) of nicotonic 
acetylcholine receptors could no longer be achieved. With this in mind I decided that we should test 
the effect of 8-bromo-cADPR after prior induction of HPV in arteries without endothelium (to remove 
confounding effects of endothelium derived vasoactive agents). Once initiated, the maintained phase 2 
constriction was, to my relief and excitation, reversed by 8-bromo-cADPR in a concentration-dependent 
manner. The threshold concentration for partial inhibition of HPV was 3 µM, which delivered all-or-
none block by pre-incubation, while complete reversal of HPV was achieved at 100 µM (Figure 5). As 
indicated above, outcomes were analogous to the action of competitive antagonists at the skeletal 
neuromuscular junction, that told us so much about the importance of junctional complexes to 
intercellular signalling [95,97–99], and where neuromuscular transmission is compromised once a 
critical mass of skeletal muscle nicotinic acetylcholine receptors are blocked. Could there be an 
intracellular junction of the SR that is critical to the induction of HPV, in which RyRs play a role similar 
to that of junctional nicotinic acetylcholine receptors? We concluded that our data for 8-bromo-cADPR 
were consistent with this idea. We proposed that a similar “margin of safety” may therefore be built 
into HPV through signal transmission across some form of intracellular junction, and in a manner 
coordinated through the activation of a subpopulation of RyRs. We suggested [24] that this might allow 
for the cADPR-dependent component of HPV to be initiated in an all-or-none manner, and thus offer a 
plausible explanation for the all-or-none block of HPV by 8-bromo-cADPR, providing its primary 
action was to block: 
“the activation by cADPR of a certain proportion of RyRs” that is critical to the initiation of HPV. 
and 
“cADPR-dependent calcium mobilisation from a sub-population of RyRs” that serve a unique and 
specific function in the context of HPV. 
This was pertinent to the wider picture derived from further consideration of 
isoprenaline-induced vasodilation and HPV, which led to the following postulates: 
“b-adrenoceptor signalling targets cADPR synthesis to a particular (read distinct) RyR subtype in 
the “peripheral” SR that is in close apposition to BKCa channels in the plasma membrane” [25]; 
“cADPR-dependent vasoconstriction results from the activation of a discrete RyR subtype 
localised in the “central” SR…”[25]; 
An SR compartment... “in close apposition to the plasma membrane, (is) served by a SERCA pump 
that is sensitive to cyclopiazonic acid” [23]; 
An SR compartment...“in close apposition to the contractile apparatus is served by a SERCA pump 
that is insensitive to cyclopiazonic acid” [23]; 
Thereafter I proposed that [23]: 
Phase 1 of HPV might be mediated by the mobilisation of calcium from an SR compartment served 
by a cyclopiazonic acid-sensitive SERCA, that is inhibited by hypoxia due to a fall in ATP supply 
proximal to the plasma membrane 
and  
The phase 2 constriction driven by cADPR-dependent SR calcium release therefore requires the 
presence of a second, spatially segregated SR calcium store that is served by a discrete, cyclopiazonic 
acid-insensitive SERCA pump that recycles calcium locked into the cell by inhibition during hypoxia 
of the cyclopiazonic acid-sensitive SERCA operating at SR juxtaposed to the plasma membrane. 
Only time and further investigations would determine whether or not this was indeed the case. 
 
Figure 5. Pre-incubation of pulmonary artery rings with 8-bromo-cADPR blocks hypoxic pulmonary 
vasoconstriction (HPV) in an all-or-none manner (left hand panels). By contrast, when applied after 
prior induction of HPV in pulmonary arteries without endothelium, 8-bromo-cADPR reverses HPV in 
a concentration-dependent manner (right hand panel). 
8. Location, Location: Dispense with the Wax and Shine Some Light on Here 
In certain cell types, such as smooth muscles, evidence had long suggested that at least two 
spatially segregated and independently releasable subcompartments of calcium may exist within the 
SR network, perhaps supplied by different, pharmacologically distinct types of SERCA pump [75–79]. 
Moreover, previous studies on acutely isolated airway smooth muscles [81,82] and our own similar 
studies on pulmonary arterial myocytes [25] suggested that b-adrenoceptor activation preferentially 
raised intracellular calcium at the perimeter of cells, proximal to the plasmalemma. However, such 
proposals had gained little traction, even though emerging evidence indicated that a single cell type 
could express SERCA2a, SERCA2b [143] and a wider variety of intracellular calcium release channels 
than previously thought. In some cases all three RyR subtypes were present [100,101], in combination 
with one or more of the three IP3R subtypes [25,77,102]. 
I considered this information in the context of the pharmacological insight provided by 
8-bromo-cADPR, and decided to explore the possibility that the functional segregation of SR calcium 
stores could be very effectively achieved through the deployment of spatially segregated subtypes of 
RyR and SERCA. At this point I was supported by a new crew at the bench, namely Nick Kinnear and 
Jill Clark, and further aided by the kind gift during 2002 of affinity purified sequence-specific antibodies 
against RyR1, RyR2 and RyR3 from Sidney Fleischer, and sequence-specific antibodies against 














SERCA2a and SERCA2b from Frank Wuytack. With these tools at our disposal we then developed 
semi-quantitative approaches by which we could assign spatial locations to each RyR and SERCA 
subtype. Briefly, we analysed the relative density of labelling for each within one of three designated 
regions of the cell, the subplasmalemmal region (within 1µm of the plasma membrane), the perinuclear 
region (within 1µm of the nucleus) and the extra-perinuclear region (everything that lay in between). 
8.1. The SERCA Circus 
One could not have wished for more strikingly different outcomes for SERCA2a and SERCA2b. 
Our analytical nous was hardly required to draw a conclusion. Visual inspection of deconvolved Z 
sections and three-dimensional (3D) reconstructions of immunofluorescence labelling was sufficient. 
SERCA2a was restricted to perinuclear regions, while SERCA2b was located proximal to the 
plasmalemma (Figure 6). 
 
Figure 6. Example cells showing labelling for SERCA2a (left hand series of panels) and SERCA2b (right 
hand series of panels) in pulmonary arterial myocytes. In each case, from left to right, a bright field 
image, z section, 3D reconstruction and 3D digital representation of labelling colour coded by region of 
the cell are shown. Nucleus identified by DAPI labelling (navy blue). Scale bar, 10 µm. 
Semi-quantitative analysis of their density of labelling by region simply confirmed what we could 
see with our own eyes [102]. The vast majority of SERCA2b labelling (~70%) lay within the sub-
plasmalemmal region, with ~8% extra-perinuclear and ~20% perinuclear. In marked contrast, SERCA2a 
labelling was almost entirely (~90%) restricted to the perinuclear region. Therefore, native SERCA2b 
must feed the SR proximal to the plasma membrane, where cADPR must facilitate the 
calcium-dependent component of vasodilation in response to b-adrenoceptor activation (Figure 7). If 
so, then SERCA2b must represent the cyclopiazonic acid sensitive SERCA, perhaps due to its location 
proximal to the plasmalemma rather than by any selective pharmacological action per se. By contrast, 
SERCA2a clearly supplies deeper, perinculear SR and most likely represents the cyclopiazonic 
acid-insensitive SERCA that supplies the component of SR critical to HPV; perhaps spared simply 
because the duration of pre-incubation allowed was insufficient to attain an effective concentration 
anywhere except at the periphery of the cell [102]. 
So, why might hypoxia mobilise calcium from two discrete SR compartments? Well, it appeared 
that the same cyclopiazonic acid-sensitive SR store was utilised during phase 1 of HPV and vasodilation 
in response to b-adrenoceptor activation. It is possible, therefore, that SR calcium release by hypoxia 
serves two purposes. Hypoxia may primarily trigger constriction by calcium release from a central SR 
compartment that is in close apposition to the contractile apparatus and served by a cyclopiazonic acid-
insensitive SERCA pump (SERCA2a). A secondary action of hypoxia could be to deplete and/or block 
filling of a peripheral SR compartment by inhibition of a cyclopiazonic-acid-sensitive SERCA pump 
(SERCA2b) that lies in close apposition to the plasma membrane, and normally facilitates vasodilation 
by removing cytoplasmic calcium to the peripheral SR (Figure 7). This could explain why pulmonary 
artery dilation by b-adrenoceptor activation is attenuated by hypoxia [103], and HPV is enhanced by 
cyclopiazonic acid [104] yet abolished by SERCA inhibition with thapsigargin [105]. 
 
Figure 7. Schematic representation of an early two compartment model developed to explain the curious 
pharmacology of 8-bromo-cADPR and cyclopiazonic acid. 
8.2. To be Three RyRs 
Analysis of the distribution of RyRs by subtype was a little more problematic, as they were not so 
cleanly separated. Adding to this, two years into our study I discovered to my surprise, that Sid 
Fleischer had provided James Sham with samples of his RyR antibodies, for the same purpose as that 
which I had outlined to him some years earlier. Sid apologised for this oversight, caused by his 
forgetting the precise nature of our project; which perhaps argues in favour of completing material 
transfer agreements even with supporters and friends. Thankfully, James’ laboratory completed a 
qualitative analysis of labelling in primary cultures of pulmonary arterial myocytes [106], which did 
little more than confirm earlier studies that had identified the expression of all three RyR subtypes in 
arterial myocytes [100,101]. As we will see below, cultured myocytes are an altogether different model 
when compared to acutely isolated cells. Therefore, Nick and Jill, independent of each other, ploughed 
on with their exhaustive, comparative analyses of RyR subtype distribution which confirmed the 
following outcomes [102,107]. 
By density of labelling (Figure 8) RyR1 was the primary subtype targeted to the sub-plasmalemmal 
region of pulmonary arterial myocytes (3–5-fold higher levels than RyR2 and RyR3). This is consistent 
with a role for RyR1 in facilitating vasodilation in response to b-adrenoceptor activation. Accordingly, 
our findings and those of others suggested that of the available RyRs, RyR1 is most sensitive to 
activation by cADPR [86,108,109]. By contrast, cADPR does not appear to activate RyR2, rather it 
increases the sensitivity of RyR2 to activation by calcium, and thus facilitates signal propagation along 
arrays of RyR2 clusters by calcium-induced calcium release (CICR) [86,90,109]. RyR3 is, much like 
RyR1, activated by cADPR, albeit at slightly higher concentrations [108]. However, we detected little 
or no RyR3 within 1µm of the plasmalemma, which argues strongly against a role for RyR3 in 
facilitating calcium release from subplasmalemmal SR in support of vasodilation. We gained further 
insights from the studies of others on the kinetics of RyR activation. Under matched conditions the 
threshold for activation of RyR1, RyR2 and RyR3 appears similar, with channel activation when 

































insensitive to CICR. It exhibits relatively little gain in probability of opening (0–0.2) with increasing 
cytoplasmic calcium concentration, while mean open times increase only twofold over the activation 
range for RyR1 [110–112]. Adding to this the IC50 for inactivation of RyR1 is ~1 µM [110,111]. Moreover, 
it is evident that propagation of calcium signals away from discrete RyR1 clusters can be limited by 
proximal RyR1 binding partners, the organisation of the SR and proximal plasmalemma, and the 
presence or absence of structures that span these two membranes (for review see [112,113]). Therefore, 
all things considered, it appeared most likely that cADPR-dependent activation of RyR1 offered the 
most likely path through which SR calcium flux might recruit plasmalemmal BKCa channels, to thus 
deliver membrane hyperpolarisation, calcium removal from the cell (SR emptying) and ultimately 
vasodilation. That said, significant levels of RyR1 were present in the extra-perinuclear region of 
pulmonary arterial myocytes, and to a lesser extent in the perinuclear region. It was therefore evident 
that RyR1 may also contribute in some way to the regulation of calcium signalling in other regions of 
the cell, a matter which we will return to later. 
RyR2 was found to be primarily located within the wider extra-perinuclear region of pulmonary 
arterial myocytes (Figure 8). The density of labelling for RyR2 within this region was 3–4 fold higher 
than that for RyR1 and RyR3, and fell 2 and 5 fold either side in the subplasmalemmal and perinuclear 
regions, respectively [102,107]. This appeared consistent with a role for RyR2 in signal propagation and 
myocyte contraction, particularly when one considers excitation-contraction coupling in cardiac 
muscles, which is so precisely coordinated by RyR2 clusters that carry propagating calcium waves by 
CICR [5,9,112,114]. Critical in this respect is the 0.5µm spacing between RyR2 clusters, its relatively low 
EC50 for CICR, low sensitivity to inactivation by calcium and high gain in open probability with 
increasing calcium concentration, which together ensure that once initiated a propagating calcium 
wave is less prone to failure than when carried by other RyR subtypes [110–112,114]. We concluded, 
therefore, that RyR2 most likely functioned to carry propagating global calcium waves in support of 
contraction in pulmonary arterial smooth muscles. Supporting this, as mentioned above, it is evident 
that cADPR does not activate RyR2 per se, rather it facilitates CICR via RyR2 by increasing its sensitivity 
to activation by calcium, which may facilitate the propagation of calcium waves once initiated [86,109]. 
This left us with a clear question to resolve. In the context of HPV and in the absence of calcium 
influx from the extracellular milieu, where could the trigger calcium necessary for stable RyR2 
recruitment arise from, and with the required margin of safety? 
In this respect, I excluded RyR1 as the source of trigger calcium for little good reason, other than 
our conclusion that subplasmalemmal RyR1s most likely facilitated calcium-dependent vasodilation. 
This left RyR3. Significantly, the density of RyR3 labelling declined markedly (between 4- and 14-fold 
by region) outside the perinuclear region of the cell (Figure 8 [102,107]). Irrespective of the mechanism 
of RyR3 activation, therefore, once recruited it seemed unlikely that RyR3 would function to carry a 
propagating calcium wave far beyond the point of initiation. This sat well with the marked increase in 
density of labelling for RyR2 within the extra-perinuclear region when compared to the perinuclear 
region. In short, RyR2 might function to receive calcium from RyR3. A plausible solution, given that a 
discrete signalling pathway for activation of perinuclear RyR3s could be delivered by regions of the 
plasmalemma that are necessarily juxtaposed to perinuclear SR where the nucleus sits. But how might 
RyR3 be differentially activated? 
In 2004 we were presented with one possibility, through the discovery by Nick Kinnear and I of 
lysosome-SR nanojunctions in pulmonary arterial myocytes (Figure 9 [115,116]), during investigations 
that were informed by the previous publications of Grant Churchill on lysosome-ER coupling in sea 
urchin eggs [117,118]. Lysosome-SR nanojunctions appeared to be critical to the action of the second 
calcium mobilising pyridine nucleotide previously discovered by HC Lee and co-workers, nicotinic 
acid adenine dinucleotide phosphate (NAADP) [119], and were primarily formed by the interaction of 
dense lysosome clusters with perinuclear regions of the SR that were rich in RyR3 (Figure 9 [107]). 
 
Figure 8. Example cells showing labelling for RyR1 (upper panels), RyR2 (middle panels) and RyR3 
(lower panels) in pulmonary arterial myocytes. In each case, from left to right, a bright field image, 3D 
reconstruction and 3D digital representation of labelling colour coded by region of the cell are shown. 
Nucleus identified by DAPI labelling (navy blue). Scale bars, 10 µm. 
In short, it appeared that lysosome-SR nanojunctions provided a trigger zone, or intracellular 
synapse, for induction of calcium signals. Accordingly, we established that SR resident junctional 
RyR3s are activated when lysosomal calcium stores are mobilised by NAADP, with extraperinuclear 
RyR2s likely required to carry propagating calcium waves beyond this perinuclear region [107,115]. 
 
Figure 9. Example images showing lysosome-SR nanojunctions. Left hand image shows enlarged 
segment of an acutely isolated pulmonary arterial myocyte, that identifies nanojunctions (yellow) 
between LysoTracker Red labelled acidic stores and Bodipy-ryanodine positive SR in an acutely isolated 
pulmonary arterial myocyte. Dashed blue rectangle (vertical axis, 0.5 µm) identifies a Lysotraker Red 
labelled organelle and Bodipy-ryanodine labelled SR in the same focal plane, but separated by ~0.5 µm. 






Lysosome-RyR3 clustersLysoTracker Red-Bodipy Ryanodine colocalisation
for lysosomes (aIGP120), RyR3 and the nucleus (DAPI, navy blue), that identifies lysosome-RyR3 
clusters colour coded by region of the cell. 
While presenting these findings to the great and the good of Robert Wood Johnson Medical School 
in New Jersey during 2005, my host and good friend Jianjie Ma suggested that he might have a good 
collaboration for me. On returning to the UK a conference call was organised by Jianjie, during which 
I was introduced to Mike Zhu, who had cloned Two Pore Channel 2 (TPC2) some years earlier and 
demonstrated that it was targeted to lysosomes. Mike had then hit a brick wall, due to the fact that he 
had no way of examining the functional role of TPC2 inside cells. My lab offered the necessary 
approaches, namely intracellular dialysis of second messengers from a patch pipette and parallel 
calcium imaging. Mike promptly supplied HEK293 cells that stably over-expressed human TPC2. With 
this model at my disposal and two new recruits to deploy, namely in Peter Calcraft (PhD student) and 
Chris Wyatt (post-doc), my lab became the first to demonstrate that NAADP gated lysosomal calcium 
release in a TPC2-dependent manner, which was confirmed using siRNA knockdown of TPC2 and 
supporting pharmacological interventions [120,121]. I then, with Mike’s prior approval, invited Antony 
Galione to join our collaborative team, with a view to his lab confirming that TPC2 was an NAADP 
receptor by radioligand-binding assay. I was aware that Antony had been looking for a candidate 
NAADP receptor for years, so it seemed only right to repay him for his previous support of my work. 
The rest, one could say, is another history [122–124]. 
Could NAADP-dependent activation of TPC2 within lysosome-SR nanojunctions offer a logical 
solution to our conundrum? Well yes, providing hypoxia triggers lysosomal calcium release through 
TPC2, which is then amplified through RyR3 activation by CICR, such that a propagating calcium wave 
is initiated by all-or-none recruitment of arrays of RyR2 clusters that span the wider cell, and in a 
manner that could be facilitated by cADPR. Indirect support for this view was provided by the 
identification of frequent discharge sites (FDS) in the perinuclear region of visceral and vascular 
myocytes, which were generally devoid of mitochondria [125], but, as we had now shown, replete with 
large lysosome clusters [107,115]. A role for lysosome-SR nanojunctions seemed all the more plausible 
when mTORC1, which is inhibited by AMPK, was implicated in the progression of hypoxic pulmonary 
hypertension [126,127]. Unfortunately, however, science is never that simple. Our subsequent 
unpublished studies indicated that the putative, non-selective NAADP antagonist NED-19 did not 
affect hypoxia-evoked constriction of isolated pulmonary artery rings, while others found that HPV 
remained unaltered after pre-incubation with two putative, non-selective NAADP antagonists [59]. 
Adding to this, using spectral Doppler ultrasound we recently found acute HPV in-vivo in mice to 
remain unaffected following global deletion of the gene (Tpcn2) that encodes TPC2 (unpublished). In 
short, if TPC2 plays a role in acute HPV it is a subtle one. Alternatively, there may be redundancy of 
function within the system, perhaps through the expression of alternative lysosome-resident, calcium 
permeable channels such as TRPML1 [128–131] and TRPM2 [132,133], each of which has been proposed 
to couple to RyRs and impact smooth muscle function and vascular reactivity. In this respect it is 
notable that mTORC1-dependent modulation of autophagy impacts pulmonary vascular remodeling 
[126,127], given that inhibition of mTORC1 [134] may regulate lysosomal TPC2 [120] and TRPML1 
[135]. Therefore, while lysosomal calcium flux may not be required for HPV, it likely contributes to the 
development of hypoxic pulmonary hypertension. 
If neither TPC2 or lysosomal calcium flux is required for induction of acute HPV, could activation 
of RyR3 by cADPR be key to the all-or-none block of HPV by 8-bromo-cADPR? Well, we now know 
that RyR3 is activated by cADPR, and at slightly higher concentrations than required to activate RyR1 
[108]. Accordingly, intracellular dialysis from a patch pipette of low concentrations of cADPR increases 
cytoplasmic calcium concentration at the perimeter of pulmonary arterial smooth muscles [25], while 
higher concentrations of cADPR initiate a global calcium transient [134]. Therefore, an alternative 
explanation could be that cADPR-dependent activation of junctional clusters of RyR3 might be critical 
to the induction of HPV, through subsequent recruitment by CICR of extra-junctional arrays of RyR2 
clusters. If RyR3 clusters are organised into discrete active units or couplons (for review see [112]), then 
this could indeed explain the all-or-none block of HPV by 8-bromo-cADPR. Once HPV is initiated, 
cADPR accumulation could then act to facilitate regenerative, propagating calcium waves by 
sensitising RyR2s to CICR. Blocking the latter could plausibly explain the concentration-dependent 
reversal of HPV by 8-bromo-cADPR, following its initiation. In short, activation of perinuclear RyR3 
couplons alone could provide a “margin of safety” for all-or-none recruitment of extra-junctional RyR2 
clusters and reduce the probability of false events being initiated. Moreover, such a model would allow 
discrete, cADPR-dependent activation of peripheral RyR1s in support of vasodilation. 
While the studies of others have confirmed the regional distribution of SERCA and RyRs in 
pulmonary arterial smooth muscles [136] (see also airway smooth muscles [137] and cerebral artery 
smooth muscles [138]), and the critical role in HPV of SR calcium release via RyRs [59,104,139], 
outcomes for studies using knockout mice have been perplexing. Briefly, gene deletion strategies have 
suggested a prominent role in HPV for RyR1 [140], RyR2 [141] and RyR3 [142]. A role in HPV for all 
three RyR subtypes seems highly unlikely, but one never can tell, especially when so many studies fail 
to distinguish between phase 1 and phase 2 of this response. So, we have arrived at one plausible 
mechanism, but without critical evidence in support of a role for lysosome-SR nanojunctions, the nature 
of the junctional complex involved remains elusive. 
9. Another Twist in the Tale 
In support of our immunofluorescence labelling we carried out RT-PCR and Western blots, 
supported by the forever positive Gordon Cramb, and his lucky white heather. RT-PCR identified 
transcripts for SERCA1, SERCA2a, SERCA2b and SERCA3 in whole arteries without endothelium 
[102]. By contrast, our sequence-specific antibodies identified only SERCA2a and SERCA2b on Western 
blots of pulmonary artery homogenates that excluded the nuclear fraction, in agreement with previous 
studies on other vascular smooth muscles [143]. Jill Clark had, however, proceeded with 
immunofluorescence assays for all SERCA using acutely isolated pulmonary arterial myocytes. During 
2004 she presented me with a number of beautiful images of 3D reconstructions of DAPI labelled nuclei 
that identified odd bands of labelling for SERCA1 across the outer surface of the nucleus (three animals, 
n = 10 cells). No labelling was evident in any other part of the cell, so I dismissed this as non-specific 
labelling, much to Jill’s evident disappointment. A couple of months later I was to eat my words. 
During one particular lab meeting Nick Kinnear was taking me through his data analysis on RyR1 
distribution in 3D reconstructions of pulmonary arterial myocytes. He had applied a digital skin/mask 
to better highlight RyR1 distribution and removed all labeling smaller than 100 nm3. The bar chart 
(mean ± SEM) in Nick’s Excel spreadsheet indicated a massive amount of RyR1 in the perinuclear 
region of the cell, yet there appeared to be little or no labelling in the perinuclear region of the 3D image 
of the example cell he had chosen. I pointed this out to him, but he struggled to dismiss the data in the 
spreadsheet. I interrupted Jill’s daydream by asking her to have a look, “Do you understand where my 
concern lies?”. She said yes, and I told her to explain it to Nick, find out what the discrepancy was and 
then come and find me. Sometime later, maybe a week but no more, Jill appeared in my office and told 
me they had something to show me. I told her I was about to give a lecture, my adrenaline was up, and 
that it was perhaps not the best time. She insisted, and said I would be happy with what they’d found. 
She was right but I was also perplexed, yet again. 
Nick and Jill had created a movie in which the cell labelled for RyR1 was rotated, the DAPI channel 
removed, and then the cell rotated once more (Figure 10). This revealed a tubular network of labelling 
within the boundary of the nucleus. I recalled the SERCA1 labelling Jill had shown me earlier. They 
were ahead of me, and the movie revealed a similar tubular network of labelling within the nucleus 
(Figure 10). No such network was observed in any cell labelled for RyR2, RyR3, SERCA2a or SERCA2b. 
I asked Jill if she’d retained the nuclear fraction removed from the homogenates used for her previous 
Western blots. Like all good scientists she had, and when this fraction was run it revealed a very faint 
band for SERCA1 [144]. 
Jill went on to load the lumen of the SR with Calcium Orange, which revealed a clear tubular 
network that appeared to span the nucleus within living cells, but there was no membrane permeable 
marker for the nucleus of living cells available at this time. I didn’t know how to take this work forward, 
so I decided to exclude any comment on nuclear labelling from our subsequent publications [102,107], 
“sat back” and waited for a day when I could further explore this signalling domain, hoping that no-
one would beat me to the punch. 
 
Figure 10. Example cells showing labelling for SERCA1 (left hand panels) and RyR1 (right hand panels) 
in pulmonary arterial myocytes. In each case, upper panels show, from left to right, a bright field image, 
and 3D reconstructions with and without DAPI labelling (navy blue = nucleus). Lower panels show 3D 
digital representation of labelling colour coded by region of the cell. Scale bars, 10 µm. 
By chance, that same year I was invited to give a talk at a symposium in honour of the pending 
retirement of Tom Bolton and Alison Brading, both of whom had been very kind in their advice and 
guidance to me, during my time at the Pharmacology Departments of St George’s Hospital Medical 
School and Oxford, respectively. I was thrilled to be invited and sought to put together my best slide 
presentation yet. It was a fortuitous moment in time, because during one coffee break I was approached 
by an elder Dutch gentleman, Casey van Breemen. Casey said he liked my talk, suggested that we 
collaborate, and asked me to drop him an e-mail after the conference had finished. Due to my circuitous 
route into the field of smooth muscle calcium signalling (Oxford, and beyond for that matter) I had no 
detailed knowledge of Casey’'s work, even though I had sat through his talk, all too blindly focused on 
the delivery of my own. However, Casey had given me his card, and I later e-mailed him. I then realised 
he was based in Vancouver, where I had booked a holiday ahead of Experimental Biology 2006. I visited 
UBC Vancouver, gave a seminar, and met Nicola Fameli for the first time. Then, in 2008 Casey invited 
me out to Vancouver again, and this time paid for my flight and accommodation. During this visit I 
decided to show Casey and Nick the nuclear labelling for RyR1 and SERCA1. Casey advised me not to 
show this to anybody else before a paper was submitted, not that I needed any such advice. 
10. We will be Fine, its Nano Time: even though “NAScA” Say We Out of Line 
I had learned that Casey, Nick Fameli and I shared a common interest in segregated signalling 
domains within cells, Casey having been the first to characterise plasma membrane (PM)-SR 
nanojunctions in smooth muscles (for historical perspective see [145,146], while I had conceived of and 
identified lysosome-SR nanojunctions while pursuing our independent evidence of calcium signalling 
within discrete cytoplasmic “microdomains” (for historical perspective see [23]). Nick Fameli was not 
a biologist, but a physicist with expertise in computer modelling who had been employed by Casey to 
apply such modelling in the further examination of how PM-SR junctions may function to adjust the 
calcium load within the SR lumen, by studying “what we could not yet see”. We further developed our 
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joined-up thinking during (for me) late night Skype sessions from my office, now at the University of 
Edinburgh, while Casey and Nick enjoyed their morning coffee. During these discussions I was 
introduced to considerations of not microdomains, but cytoplasmic nanodomains for calcium 
signalling. On one occasion Casey could not make the allotted Skype time, so Nick Fameli took me 
through his latest modelling of calcium exchange across cytoplasmic nanodomains. He was explaining 
that once a junctional membrane pair was separated by more than 50 nm junctional integrity weakened 
in a manner that could be compensated for by increasing the number of SERCA pumps, but above 200 
nm the capacity for site-specific calcium exchange was not just reduced but lost entirely. I cut him short 
to ask “Where does the calcium go then?”. Nick replied “it diffuses out of the sides”. To be precise, the 
probability of random diffusion of calcium away from the junction formed by the membrane pair was 
higher than that for capture by SERCA when the junctional membrane separation was increased from 
200 nm to 400 nm, irrespective of the density of SERCA pumps in the SR membrane [147,148]. Eureka, 
it was not just the “nanodomain” but the “nanojunction” that was critical to our thinking! 
Nanojunctions not only acted to direct calcium signalling, but also restricted the random diffusion of 
calcium away from the cytoplasmic space demarcated by them. We hastily arranged another Skype 
meeting with Casey to discuss this “revelation”. Our ongoing discussions led to the “Panjunctional 
Sarcoplasmic Reticulum” hypothesis that was framed in an invited review for the Journal of Physiology 
[22], which, at my insistence, excluded any consideration of nuclear calcium signalling. In essence this 
hypothesis was built around the proposal that cellular membrane-membrane nanojunctions are formed 
by the SR at defined “target sites” to deliver highly localised and functionally segregated calcium 
signals, with the functional specification of a given signal determined both by the constraints on 
diffusion imposed by the nanojunction itself and by the calcium signalling machinery incorporated 
within a given junctional complex. Nanojunctions are defined by their distances of separation and had 
been identified not only between the S/ER and the PM, but a variety of organelles including lysosomes, 
mitochondria and the nucleus [22]. We knew at the time that the underlying mechanisms of signal 
generation were likely more elaborate in nature than we could possibly envisage, but evidently relied 
on the strategic targeting to their designate nanojunction of macromolecular complexes that 
incorporate different types of calcium transporters and release channels, each of which may be 
characterised by different kinetics and affinities for calcium, and may in turn be differentially 
modulated by their respective binding partners, second messengers and enzymes [102]. This is self-
evident when one considers, for example, the fact that in arterial and arteriolar smooth muscles alone, 
we now know that intracellular calcium signalling is coordinated by the gating of: 
Two of the three known S/ER resident IP3 receptors (IP3R1-3) by inositol 1,4,5 trisphosphate (IP3) 
[149–153]; 
Up to three S/ER resident ryanodine receptor subtypes (RyR1-3) [100,106,107,153] by calcium 
and/or cADPR [24,25,91,107,108,116,154]; 
Endolysosome targeted two pore channel (TPC) subtypes 1 and 2 by either NAADP 
[115,116,121,134,155], phosphatidylinositol-3,5-bisphosphate (PI3,5P2) [156], or mTORC1 [134,157]; 
 
Endolysosome targeted TRPML1 [128–131] and TRPM2 [132,133] by mTORC1 and/or ADP-ribose; 
The mitochondrial calcium uniporter [158,159]. 
Furthermore, the expression pattern of calcium release channels and pumps in smooth muscles 
may vary between regions in the same vascular bed [153] and from one vascular bed to another 
[102,137,153,160–162]. In short, variations in the prevalence of nanojunctions, their ultra-structure and 
their respective molecular machinery could explain, in part, both functional heterogeneity 
[25,153,160,161,163] and plasticity [22,136] of smooth muscles, and wider differences evident between 
smooth muscles and other cell types [13]. 
With regard to the likely importance of nanojunctions themselves to cellular communication, we 
need look no further than the neuromuscular junction, where the critical role of nanojunctions in 
intercellular communication has been evident for nearly a century [11]. It is the organisation of these 
junctional membranes that proved to be so critical to neuromuscular transmission through their 
coordination of the release, receptor interactions and reuptake of acetylcholine [95,97–99]. Here, 
electron micrographs indicate that the pre- and post-junctional membranes are approximately 20nm 
apart, and extend more or less parallel to each other over several hundred nm. It is important to note, 
however, that junctional dimensions seen within electron micrographs may be smaller than they are in 
reality, due to sample dehydration. 
Given the above it is surprising that so little attention has been paid to the role in intracellular 
signalling of the plethora of junctions formed between intracellular membranes, beyond 
acknowledging that there are “contact sites” that may aid the direction of ion fluxes, exchange or the 
action of other messengers. The one notable exception is of course in the process of 
excitation-contraction coupling in skeletal and cardiac muscles, where the junctional complexes formed 
between T-tubules of the sarcolemma and terminal cisternae of the SR are well documented, and are 
equally critical to the coordination of excitation-contraction coupling as the neuromuscular junction 
itself. In each instance electron micrograpahs suggest that the junctional membrane pair are separated 
by ~20 nm [164–168]. There is, however, one important distinction between skeletal and cardiac muscles 
that must be mentioned in terms of the mechanism by which calcium is mobilised during excitation-
contraction coupling, and this will undoubtedly have resonance with respect to our future 
understanding of the versatility of signalling across all intracellular nanojunctions. Against earlier 
predictions, it is now evident that the sarcolemma-SR nanojunctions of skeletal muscle allow for the 
transfer, through non-covalent association, of electrostatic charge between sarcolemma resident 
dihydropyridine receptors and SR resident RyR1s (see for example [169–171]), which ultimately gates 
calcium release from the SR via RyR1 couplons [112]. By contrast, the sarcolemma-SR nanojunctions of 
cardiac muscle support what is generally regarded as the classical form of junctional coupling, namely 
agonist-receptor interactions, by targeting calcium influx to RyR2 clusters located on the terminal 
cisternae of the SR which, in turn, trigger a propagating calcium wave and contraction by further CICR 
from the SR via arrays of RyR2 clusters, each RyR2 cluster separated from the other by ~500 nm [9,114]. 
Whatever the mechanism of transduction, electrostatic or agonist-receptor gating mechanisms, these 
sarcolemma-SR junctions represent the archetypal intracellular nanojunctions, with each one being 
separated by ~20 nm (not allowing for reductions through dehydration) and clearly designed to 
accurately deliver calcium to one defined target above all else. 
Already there appears some consistency of form and function, so why nanojunction? As indicated 
above, following more than 15 years of discussion on experimental data and modelling outcomes with 
Casey and Nick Fameli, our firm assertion is that all active nanojunctions constitute at least two adjacent 
biological membranes that demarcate a highly structured cytoplasmic space, with nanotubes perhaps 
representing the optimal operational unit in biology. To maintain junctional integrity, it is now clear 
that the optimal operating limit for intracellular nanojunctions is £ 200nm in width, typically a few 100 
nm in extension, and that either side the membrane pair must contain complementary ion transporters 
and channels that serve to deliver and/or receive site-specific calcium signals. As described previously, 
it is evident that both the ultra-structure, the electrostatic properties of each membrane of the junctional 
pair and the macromolecular composition of transport molecules embedded in their limiting 
membranes will ensure that cytoplasmic ion concentrations, and calcium in particular, are determined 
locally. Calcium flux may thus be specifically targeted to “receptive sites” with great accuracy, due in 
no small part to the ability the nanojunction to restrict diffusion of calcium away from the cytoplasmic 
space thus demarcated [147,172]. 
11. PM-SR Nanojunctions of Vascular Smooth Muscles 
It is 40 years since analysis of electron micrographs first identified narrow cytoplasmic spaces (~20 
nm across) between the PM and the superficial SR of smooth muscles [173,174]. This led to Casey van 
Breemen’s “superficial buffer barrier” hypothesis [145,175–177], which posited that restricted diffusion 
from this “nanospace” allows the superficial SR to limit direct calcium flux from the PM to the 
myofilaments [176]. This hypothesis has now received support from studies on a variety of smooth 
muscle types. PM-SR nanojunctions are abundant in myocytes and appear to demarcate a cytoplasmic 
nanodomain that coordinates the delivery of calcium to, or the removal of calcium from the SR 
[146,178–182]. In doing so these nanojunctions not only serve to regulate SR luminal calcium load, but 
also hyperpolarisation and relaxation, depolarisation and vasomotion, and, as we will see, may 
influence gene expression in parallel, in series or in isolation. PM-SR nanojunctions are therefore 
polymodal [71,145. They may support either vasodilation or vasoconstriction, respectively, through the 
capacity of the SR to not only empty when overloaded with calcium [183] or signalled to do so by 
vasodilators [25], but to reload its calcium store once depleted [148,184]. If we take this as an example 
of what is possible, then it is evident that all nanojunctions may exhibit similar levels of plasticity. 
12. China Girl: How the Cell-Wide Web was Weaved 
In 2010 I picked up the “baton” left by Jill Clark, by reassessing her images of the SR lumen loaded 
with Calcium Orange, which had, we presumed, revealed a tubular network within the nucleus of 
living cells. Importantly, a membrane permeable marker for the nucleus had finally been made 
available, namely the DNA marker Draq5 (Figure 11). These further studies were also aided by the 
arrival of Jorge Navarro-Dorado, who joined my lab from Madrid in order to obtain a European 
classification for his PhD. We explored the possibility that Jill had identified cytoplasmic nanotubes 
within the boundary of the Draq5 labelled nucleus using Fluo-4 to report on cytoplasmic calcium. By 
adjusting the threshold for fluorescence detection, it was evident that a network of narrow tributaries 
of cytoplasm £500 nm wide penetrated the nucleus, perhaps reflecting the path of nuclear envelope 
invaginations which I had first been introduced to in 1997 whilst viewing a new confocal microscope 
in the Dunn School of Anatomy at Oxford [185]. 
 
Figure 11. Upper panels show (from left to right) nuclear invaginations at differing orders of 
magnification, in sections through the nucleus of a pulmonary arterial myocyte in which the lumen of 
the sarcoplasmic reticulum has been loaded with Calcium Orange (Scale bars from left to right, 2 µm, 1 
µm, 1 µm). Middle panels show ER tracker and Calcium Orange co-labelelling of nuclear invaginations. 
Draq5 identifies the nucleus (blue) in each case (Scale bars, 2 µm). Lower panel, electron micrograph 
shows nuclear invaginations in a pulmonary arterial myocyte in-situ in a pulmonary artery section 
(Scale bar, 2 µm). 
I subsequently coined the name cytoplasmic nanocourses to refer to these cytoplasmic networks, 
which exhibited markedly higher levels of Fluo-4 fluorescence than the surrounding nucleoplasm, and 
could be equally well distinguished from any aspect of the wider cytoplasm, which in turn and 
invariably exhibited higher basal fluorescence than the nucleoplasm (Figure 12). This suggested that 
invaginations of the nuclear envelope might demarcate discrete signalling compartments that could be 
observed without the need for further image processing, irrespective of whether or not differences in 
fluorescence intensity resulted from differences in local cytoplasmic calcium concentration, or the 
influence of the local environment within each of these compartments on general Fluo-4 fluorescence 
characteristics [186,187]. Jorge then returned to Spain, while I finally sought direct funding to further 
these investigations, at the risk of revealing our findings to the “wider” research community. To my 
excitement and great relief, funding arrived through the award of a British Heart Foundation 
Programme Grant in 2012. I re-appointed Jorge as a post-doctoral researcher in 2013, who was joined a 
year later by a PhD student fresh from China, Jingxian Duan. 
 
Figure 12. Fluo-4 fluorescence (green) identifies cytoplasmic nanocourses within the boundary of the 
Draq5 labelled nucleus (blue) of a confocal Z section through a pulmonary arterial myocyte (left hand 
panels i-iii). A spectral intensity plot across the nucleus (right hand panel iv) shows that nanocourses 
within nuclear invaginations (NI) exhibit higher levels of fluorescence than the nucleoplasm (N), and 
cytoplasm (C) identified by the dashed line in panel iii. 
In the meantime, a new Nikon A1R+ confocal microscope had been installed in our imaging facility 
(IMPACT) at Edinburgh, which was critical to our further investigations due to the much lower signal-
to-noise and greater spatial resolution afforded by the Galvano scanner supplied with this system (for 
details see [144]). Jorge and Duan spent the first 2–3 years focused on studying calcium signals within 
raw images of nuclear nanocourses. ER Tracker labelling and Calcium Orange loading of the SR lumen 
confirmed that nuclear nancourses were demarcated by invaginations of the nuclear envelope (NE) and 
thus the outer nuclear membrane (ONM), which is continuous with the SR (Figure 11 [72,125,188]). 
These studies were allied to an investigation of the distribution along the inner nuclear membrane 
(INM) of lamin A and histone marks. Our longer-term goal being to determine whether or not calcium 
signals passed from the nuclear invaginations into the nucleus to thus modulate gene expression. How 
wrong could we be, yet again!! 
With the Nikon A1R+ set to detect those cytoplasmic nanocourses visible within the boundary of 
the nucleus, we frequently observed variegated, region-specific differences in Fluo-4 fluorescence 
intensity in the bulk cytoplasm (beyond the boundary of the nucleus). In short, highly localised, 
time-dependent and asynchronous fluctuations in Fluo-4 fluorescence intensity were evident across the 
wider cell. At first, I saw this variegated loading as an irritation that was likely due to erroneous loading 
of organelles, vacuoles and other aspects of the cells. However, cells presented like this far more 
frequently than we ever observed “uniform” loading of Fluo-4. After three years of irritation and 
periodic re-examination, I chose not to exclude such cells from further analysis as others had done 
previously (see for example [189]), rather I focused our attention on the indications derived from what 
could be seen in the clear majority. For when one suspended disbelief, it was all too clear that a variety 
of highly localised fluctuations in Fluo-4 fluorescence occurred within this variegated “map” of the cell. 
After viewing one particular cell during live acquisition, I requested that Duan carry out deconvolution 
of all Fluo-4 images within the time series acquired. She dutifully obliged; Jorge had previously stated 
that this was “impossible” and made no attempt to do so, which eventually settled arguments over first 
author status. In short, with the laser power, threshold, gain and Fmax set to highlight nuclear 
nanocourses, Duan’s further image processing revealed a cell-wide network of well-defined 
cytoplasmic nanocourses (≤400 nm across) that appeared to be demarcated by SR, and spanned the 
entire cell from the Draq5 labelled nucleus to the plasmalemma. It is worth noting here that the 
dimensions of the nanocourses we described likely provide larger estimates than reality, because 
deconvolution will not have removed all stray light. Nevertheless, this was a consistent observation, 
irrespective of cell shape or size (Figure 13). If we consider this in the context of electron microscopy, 
where preparations are dehydrated and probably report smaller distances of separation of junctional 
membranes than is reality, it seems likely that in fully hydrated cells the true dimensions of many 
nanojunctions of the SR may lie somewhere between 20 and 200 nm. 
 
Figure 13. From left to right, panels show pseudocolour representations of deconvolved z sections of 
Fluo-4 fluorescence that identify a cell-wide network of cytoplasmic nanocourses within three different 
acutely isolated pulmonary arterial myocytes, irrespective of cell size or shape. Right hand panels show 
enlarged images of two cytoplasmic nanocourses from the same cell, in which asynchronous, time-
dependent fluctuations in hotspots of calcium flux (from top to bottom) can be seen. 
During short time series’ (2–6 min; time-limited by photo-toxicity) hotspots of local calcium flux, 
~200–400 nm in diameter, were readily identifiable in pseudocolour representations of this cell-wide 
network at rest (Figure 13), the intensity of which oscillated over a time course of seconds, without 
propagating beyond the nanocourse within which a given hotspot arose. Moreover, these hotspots of 
calcium flux exhibited asynchronous temporal characteristics when compared to adjacent hotspots 
within the same nanocourse, or hotspots arising in different nanocourses. It is possible, therefore, that 
these hotspots of calcium flux might represent activity akin to the “calcium sparklets” previously 
described in visceral and vascular myocytes [125,189]. Here too, a high degree of regional variability in 
the spatiotemporal characteristics of spontaneous SR calcium release was noted, which was proposed 
to be due to the presence of discrete calcium release units that are regulated autonomously [125]. 
However, the authors of these studies concluded that junctional complexes such as the PM-SR junction 
were not required for the extensive patterns of calcium release observed. To quote: “a diffusion barrier 
per se seems an unlikely explanation for some extended patterns of release which followed the surface 
membrane, it is more likely that such events come about as a result of the spatial distribution of RyRs 
near the membrane” [189]. Our studies are consistent with both proposals, but suggest yet more. They 
demonstrate that junctional membrane complexes, variations in RyR subtype, and variations in the 
spatial distribution of RyR clusters contribute to regional variations in the pattern of calcium flux from 
local release sites in smooth muscles. Accordingly, distances of separation between hotspots for 
subplasmalemmal (~350 nm) and nuclear nanocourses (350 nm) [144] are consistent with those for 
skeletal muscle RyR1s [166], while distances of separation for extra-perinuclear (~400 nm) and 
perinuclear (~450 nm) nanocourses are significantly greater [144] and closer to those reported for 
cardiomyocyte RyR2s (0.6–0.8 µm) [114]. This is significant, because these distances of separation are 
entirely consistent with the regional distribution of RyR1 and RyR2 in pulmonary arterial myocytes 
previously reported by my laboratory and others [102,107,136]. Consistent with this, temporal 
fluctuations in the fluorescence intensity of hotspots were markedly attenuated by prior depletion of 
SR calcium stores by SERCA inhibitors and abolished upon blocking RyRs. In short, these events most 
likely reflect low level, basal calcium flux (leak) from the SR via RyRs. However, while RyRs can remain 
open for many seconds, the fastest gating events are on the millisecond time scale [190]. Therefore, the 
development of confocal systems with higher temporal and spatial resolution is required before we can 
measure the kinetics of hotspots of calcium flux with sufficient precision to determine whether or not 
they are generated by “unitary” calcium release through discrete RyRs and/or RyR clusters. 
Supporting the view that the wider network of cytoplasmic nanocourses may represent a circuit 
for cell-wide communication, it was evident that a subpopulation of LysoTracker Red labelled 
endolysosomes migrated through this network of cytoplasmic nanocourses, while, consistent with our 
previous observations [107,115], a larger, static cluster was evident in the perinuclear region of these 
cells [144]. By contrast, all MitoTracker Red labelled mitochondria formed static clusters in acutely 
isolated cells [144], as reported previously by others [191], which sit within the nanocourse network 
where they too likely form nanojunctions with the SR [192]. 
Site- and function-specific calcium signalling was confirmed using a membrane-traversing peptide 
from scorpion venom that selectively activates RyR1, namely maurocalcine [193]. Consistent with the 
distribution of RyR1s, maurocalcine preferentially increased calcium flux into subplasmalemmal and 
nuclear nanocourses (Figure 14 [144]). Maurocalcine also evoked concomitant myocyte relaxation, 
confirming our previous proposal that RyR1s might coordinate vasodilation [25,102]. By contrast there 
was relatively little change in calcium flux within even the most proximal extra/perinuclear 
nanocourses. In short, we had likely visualised for the first time unloading of SR calcium through RyR1s 
within the “superficial buffer barrier” presumed to be demarcated by PM-SR nanojunctions [145], 
which confer nanoscale path lengths and have long been predicted to coordinate calcium removal from 
the SR and thus relaxation [25,71,102,183], as well as SR refilling during prolonged contraction 
[60,148,176,184,194–198]. 
Curiously, however, over the time course of our experiments (2–6 min) maurocalcine-induced 
myocyte relaxation was not accompanied by concomitant falls in calcium flux into extra/perinuclear 
nanocourses. If anything, asynchronous calcium flux continued within these nanocourses, with 
perhaps slight increases in activity but no evidence of cell-wide signal propagation. One explanation 
for this could be that the relatively small population of RyR1s in extra/perinuclear nanocourses neither 
face nor couple with the contractile apparatus, rather they act to direct calcium flux towards PM-SR 
nanojunctions via SERCA2b and away from SR release sites occupied by RyR2s/RyR3s that guide 
myofilament contraction. 
As one might expect of a vasoconstrictor, angiotensin II induced a calcium wave that propagated 
throughout all extraperinuclear and perinuclear nanocourses, but not subplasmalemmal nanocourses, 
and triggered concomitant myocyte contraction (Figure 14). Surprisingly, however, this propagating 
signal was immediately preceded by a rapid fall in Fluo-4 fluorescence intensity within the majority of 
cytoplasmic nanocourses, except for those at the point of wave initiation. This suggests that angiotensin 
II might also act to pre-load the SR with calcium, which could be a critical step prior to induction of 
cell-wide signal propagation and myocyte contraction, and may, for example, rely heavily on RyR 
sensitisation through increases in calcium-calsequestrin binding within the lumen of the SR [199–201]. 
Importantly, angiotensin II-induced calcium signals were blocked by, you guessed it, 8-bromo-cADPR. 
Given that cADPR preferentially activates RyR1s and RyR3s [108] but can only sensitise RyR2s to CICR 
[109], it therefore seems likely that angiotensin II-evoked cADPR accumulation within extraperinuclear 
nanocourses may serve to activate local subpopulations of RyR1s and/or RyR3s [108] while delivering 
concomitant sensitisation of RyR2s to CICR [109]. In this way subsequent initiation of a propagating 
calcium signal and thus myocyte contraction could be permitted. Accordingly, prior depletion of SR 
stores with thapsigargin and block of RyRs with tetracaine abolished angiotensin II-evoked calcium 
signals [144]. 
If, however, we consider the extra-perinuclear location of the site of signal initiation in response 
angiotensin II (Figure 14), this rather surprisingly favours RyR1s over RyR3s, because RyR3s are so 
heavily restricted to the perinuclear SR. If this is the case, then the action of maurocalcine (see above) 
lends support to the view that a critical factor in the selection of vasoconstriction over vasodilation 
might be the capacity of a vasoconstrictor to pre-load the SR prior to RyR activation 
[112,199,200,202,203]. In this respect it is worth noting that the studies of others have suggested that 
cADPR might act to accelerate SR-filling by activating SERCA [204–206], although our studies have 
revealed no clear evidence of this [108]. Such an action could provide an alternative explanation for the 
all-or-none block of HPV by 8-bromo-cADPR, if 8-bromo-cADPR blocks the initiation of HPV by 
inhibiting the activity of both SERCA and RyR1,2 and 3. 
It is important to note that although the widths of all extra/perinuclear nanocourses are £400 nm 
across, when considering contraction the larger scale of nanocourses is not entirely incompatible with 
limits imposed by models of calcium flux across nanojunctions, or electron micrographs. As mentioned 
previously, calcium diffusion and signal propagation can be further limited by RyR binding partners, 
the organisation of the SR, and the presence or absence of structures that span the two limiting 
membranes of any given nanojunction (for review see [112,113]). It is therefore notable that separate 
PM regions have been described for filament attachment and caveolae [207], while the density of 
myosin filaments appears to be less in the cell periphery than in the central myoplasm [208]. In addition, 
the functional calcium-binding protein calmodulin is tethered proximal to the SR membranes that line 
myofilament arrays [209], rather than being freely diffusible in the cytoplasm. All relevant path lengths 
from the SR to calcium binding proteins, and from calcium binding protein to myofilaments may 
therefore be on the nanoscale, even if the distances of separation for the junctional membranes are 
greater than 200 nm. 
At this point it is worth highlighting a further, long-standing curiosity that remains to be resolved. 
Our studies on pulmonary arterial myocytes and those of others have demonstrated that IP3Rs do not 
couple by CICR to RyRs in this cell type [67,116], which is contrary to the findings of studies on, for 
example, venous smooth muscles [210,211]. This strongly suggests that RyRs and IP3Rs might be 
segregated in pulmonary arterial myocytes, perhaps in part by SR nanojunctions that demarcate 
discrete cytoplasmic nanocourses. 
 
Figure 14. Upper panels, from left to right, show myocyte relaxation in response to RyR1 activation by 
maurocalcine, with nanocourse-specific changes in calcium flux identified in pseudocolour 
representations of deconvolved z sections of Fluo-4 fluorescence (scale bar, 2 µm). Lower left, panels 
similarly show calcium flux during myocyte contraction induced by angiotensin II (scale bar, 3 µm). 
Lower right, panels show angiotensin II-induced increases in calcium flux within nuclear nanocourses 
of a different cell (scale bar, 1 µm). 





































As mentioned above, maurocalcine also increased calcium flux into nuclear nanocourses adjacent 
to relatively inactive perinuclear nanocourses. This further exposed the functional segregation of 
nuclear nanocourses from their nearest neighbour, through the strategic targeting of RyR1s to the outer 
nuclear membrane (ONM) that demarcates nuclear nanocourses. Against all expectations, however, 
maurocalcine-evoked calcium flux within nuclear nanocourses did not propagate freely into the 
nucleoplasm to any great extent, i.e. calcium is released across the ONM into the cytoplasmic 
nanocourses demarcated by each active invagination, but neither directly nor indirectly into the 
nucleoplasm. Consistent with this, we found no evidence in quiescent cells of hotspots of calcium flux 
propagating into the adjacent nucleoplasm. Closer inspection of calcium flux within nuclear 
nanocourses also revealed functional signal segregation in response to not only maurocalcine but the 
vasoconstrictor angiotensin II (Figure 14). Both stimuli triggered increases in calcium flux within a 
subset of nuclear nanocourses, and with distinct spatiotemporal signatures evident in each of these 
activated nanocourses. Intriguingly, with respect to angiontensin II alone we did observe evidence of 
very low-level propagation of calcium flux from nuclear nanocourses into adjacent, Draq5-positive 
nucleoplasm [144]. Therefore, it is possible that certain physiological stimuli might gate RyRs and 
pathways for trans-NE calcium flux into the nucleus, while others may not. This could offer a powerful 
mechanism for differential regulation of gene expression by different stimuli. 
The functional reasons for the isolation of nuclear nanocourses are not clear, but it may be to, for 
example, prevent wide-scale gene activation/inactivation events that could switch cells from a 
differentiated to proliferative phenotype, operated through specific changes in calcium flux. Using 
electron microscopy we observed 20–200 nm diameter invaginations, as have others [185], within the 
nucleus of arterial myocytes in-situ in arterial sections. We could distinguish invaginations of the outer 
nuclear membrane (ONM), forming open transnuclear channels, or shallow, blind invaginations of 
variable depths reaching into the nucleus (Figure 11). As the NE is a double membrane, invaginations 
also contained inner nuclear membranes (INM), with the luminal space between INM and ONM 
ranging from 10–50 nm. Jorge Navaro-Dorado labelled fixed cells for lamin A, which generally lines 
the INM, and this too revealed tubular networks that criss-crossed the nucleoplasm of these 
differentiated cells (Figure 15), in much the same way as nuclear nancourses. 
Jorge then developed, later in association with Duan, novel and exhaustive image analysis 
protocols, by which we began to examine the possibility that calcium flux across the ONM could in 
some way modulate gene expression, with insightful comment and support from Eric Schirmer. 
Normal ovoid nuclei tend to have histones carrying both H3K9me2 and H3K9me3 marks, and the 
chromatin cross-linking protein barrier to autointegration factor (BAF) associating with NE proteins 
such as emerin and making the nuclear periphery generally silencing [212–214]. Interestingly, these 
marks segregate in differentiated arterial myocytes with the H3K9me2/3 both still at the outer limits of 
the nucleus but depleted with respect to BAF, and the nuclear invaginations rich with H3K9me2 and 
BAF (Figure 15), but depleted with respect to H3K9me3 [144]. The combination of H3K9me2/3 together 
is strongly silencing, but absent the me3 mark and the me2 can reflect a poised state that has been found 
at myogenic regulators such as the myogenin promoter [215]. It is therefore possible that the 
non-propagating calcium transients in distinct invaginations in some way specifically regulate 
chromatin in differentiated cells, as the different chromatin marks are concentrated in puncta. Discrete 
H3K9me2-lamin A puncta (» 500 nm diameter) were separated by » 400 nm, while emerin-BAF puncta 
(» 400nm in diameter) were separated by » 500 nm, approximating the 350 nm spacing between the 
tetracaine-sensitive hotspots of nuclear nanocourses. Potentially calcium and/or charge responsive and 
functionally distinct chromatin domains may therefore be established by nuclear invaginations. 
Supporting this, blocking RyRs with tetracaine reduced the expression of two genes of interest, one 
encoding the DNA mismatch repair protein MutL homolog 1 (Mlh1), which can be repressed through 
interaction with H3K9me2 [216,217], and another encoding the S100 calcium binding protein A9 
(S100a9), which can be repressed by BAF [218]. 
 
Figure 15. Right hand panels, sections through a 3D reconstruction of the nucleus of a pulmonary 
arterial myocyte reveal puncta of lamin A and H3K9me2 colocalisation on a lamin A positive 
transnuclear invagination (from left to right scale bars 1 µm, 1 µm, 500nm). Left hand panels, sections 
similarly show puncta of emerin and BAF (barrier to autointegration factor) colocalisation on 
transnuclear and blind invaginations (from left to right scale bars 1 µm, 1 µm, 500nm). 
Therefore, consistent with predictions based in large part on the actions of 8-bromo-cADPR against 
pulmonary artery dilation and constriction, respectively, it is now evident that multiple coordinated 
actions may very well be delivered by distinct nanojunctions of the SR that demarcate diverse 
nanocourse networks, to thus provide for signal segregation sufficient to enable nanocourse-specific 
delivery of calcium signals with the capacity to coordinate the full panoply of cellular processes. 
14. More than this: Lost in Proliferation 
During the transition to proliferating myocytes in culture, the entire, cell-wide network of 
cytoplasmic nanocourses was lost, inclusive of all lamin and emerin positive nuclear invaginations 
[144]. These observations are therefore consistent with the idea that invaginations act to regulate anti-
proliferative genes, that is until the proliferative phenotype [219] is ready to be engaged. During 
proliferation we noted loss of S100A9 expression (but not MLH1 expression), namely the emerin and 
BAF regulated gene whose expression was attenuated by blocking calcium flux through RyRs with 
tetracaine, which is consistent with previous reports on S100A9 repression during proliferation of 
airway smooth muscles [220]. These observations, the distribution of chromatin marks and general 
tendency of NE-association to keep chromatin repressed [221,222] lends support to the view that NE 
invaginations may play a role in genome regulation and cycles of gene repression and activation. That 
this phenotypic change is delivered through reconfiguration of the cell-wide nanocourse network that 
directs calcium flux is further highlighted by: 
A switch in dependency of angiotensin II-induced calcium transients from RyRs to IP3Rs; 
Unrestricted, cell-wide SR Ca2+ release due to loss of cytoplasmic nanocourses; 
Loss of the “nuclear buffer barrier” [223] that opposed direct calcium flux into the nucleoplasm in 
acutely isolated cells. 
Accordingly, others have found that myocyte proliferation coincides with whole-scale changes in 
gene expression inclusive of decreases in lamin A [224] and RyR expression, and augmented IP3R 
expression [225]. 
15. Reviewing the Situation: Got to Pick a Pocket or Two Boys 
From a curious piece of pharmacology that was the all-or-none block of HPV by 8-bromo-cADPR, 
and the cautious proposal that outcomes may be explained by the presence of an intracellular junction 
[24], twenty years on we reveal the cell-wide web (Figure 16). 
This cell-wide network of cytoplasmic nanocourses appears to be delineated by 
membrane-membrane nanojunctions of the SR, which provide discrete lines of communication that 
span the entire cell. Functional specification may well, therefore, be determined by the constraints on 
calcium diffusion imposed by SR junctional membranes, as predicted by computer models [147], and 
by the strategic positioning of different types of calcium transporters and release channels targeted to 
them, through unique kinetics, affinities for calcium and mechanisms of regulation [11]. The structural 
elements that hold this junctional network in place remain to be determined, but there is evidence to 
suggest that junctophilins may be critical to the formation of PM-SR nanojunctions at the very least 
[226–229], while others suggest, on the basis of the action of depolymerising agents (e.g. nocodazole), 
that actin, tubulin and/or other components of microtubules may provide further structural support 
[230]. 
In pulmonary arterial myocytes calcium flux through RyR1s located within PM-SR nanocourses 
evokes relaxation with no evidence of cell-wide signal propagation, confirming the existence of a 
functional “superficial buffer barrier” [145]. Distinct nanocourses rich in RyR2s and RyR3s carry rapid, 
propagating calcium signals that cross the entire cell from pole to pole triggering myocyte contraction. 
Yet these latter signals did not enter those nanocourses demarcated by PM-SR nanojunctions, which 
constitute the superficial buffer barrier. Therefore, RyR2 subtype designation determines the capacity 
for rapid signal propagation by CICR across thus specified nanocourses, as it does so effectively in 
cardiac muscle [112]. 
 
Figure 16. Calcium signalling is analogous to quantum tunneling across a cell-wide circuit with the 
nucleus at its centre. (a) and (b), Microprocessor at the centre of a circuit board. (c) (Fluo-4, green) and 
(d) (Fluo-4, pseudocolour), show the nucleus (Draq5 in (c) only, blue) at the centre of a cell-wide circuit 
of cytoplasmic nanocourses. e, Schematic shows calcium flux across cytoplasmic nanocourses 
demarcated by junctions between the plasma membrane and sarcoplasmic reticulum (PM-SR 
nanojunction), the sarcoplasmic reticulum nanojunctions aligned with the contractile myofilaments of 
a smooth muscle and the nuclear invaginations. Angiotensin II, AngII; Ryanodine receptor, RyR; 
Sarco/endoplasmic reticulum calcium ATPase, SERCA; sodium/calcium exchanger, NCX; ADP-ribosyl 
cyclase, ARC; Myosin light chain kinase, MLCK; AT1, Angiotensin AT1 receptor; Protein kinase A PKA; 
large conductance calcium-activated potassium channel, BKCa. Panels (a) and (b) are free images. The 
schematic in panel (e) was adapted from previous versions developed and published by AME. 
Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages 
No., Advances in Pharmacology, 78, Evans AM, Nanojunctions of the Sarcoplasmic Reticulum Deliver 
Site- and Function-Specific Calcium Signaling in Vascular Smooth Muscles, 1–47 Copyright (2017), with 
permission from Elsevier. 
On one hand this allows cell-wide synchronous actions as required. On the other it may 
additionally confer the capacity for onward transfer (perhaps sampling) of a fraction of released 
calcium through SERCA that feed functionally distinct subsets of nanocourses. If we consider nuclear 
invaginations in this respect, such sampling of released calcium may serve to inform the nucleus on 
activity-dependent requirements of the cell. Invaginations of the nuclear envelope confer further 
segregated and diverse networks of cytoplasmic nanocourses that project deep into the nucleoplasm, 
which break down themselves into multiple subtypes based on emerin-BAF and lamin A-H3K9me2 
clusters, are served by a unique pairing of ONM resident calcium pumps (SERCA1) and release 
channels (RyR1) and carry calcium signals with different spatiotemporal characteristics when 
activated. Here, regulated calcium flux across the ONM into nuclear nanocourses might contribute 
additional levels of genome regulation by, for example, segregating specific chromatin types for cycles 
of reactivation in differentiated cells and providing a path for related gene repression during 
phenotypic modulation [219]. Importantly, others have confirmed the regional distribution of SERCA 
and RyRs not only in pulmonary arterial smooth muscles [136], but in airway smooth muscles [137], 
which may provide for the high degree of variability in kinetics of spontaneous SR calcium release in 
myocytes from the ileum [189] and hepatic portal vein [125]. It is also notable that previous studies 
have identified RyR1, RyR2 and RyR3 expression in cerebral arterial myocytes [138], which must at 
some stage inform current models on calcium signalling in these cells too, which for some reason rely 
solely on a consideration of RyR2 clusters, whether one considers PM-SR nanojunctions [230,231] or 
more recent “comparative” assessment of the role of lysosome-SR nanojunctions in this cell type [128]. 
Importantly, and regardless of the functional subdivision of cytoplasmic nanocourses, all path 
lengths from calcium release site to targeted signalling complex appear to be of the order of tens or 
hundreds of nanometres, with picolitre volumes of cytoplasm lying within the boundaries of each 
nanocourse [147]. Relatively small net increases in local calcium flux (1–2 ions per picolitre) will 
therefore be sufficient to raise the local concentration into the affinity ranges of most cytoplasmic 
calcium binding proteins [147]. Thus, calcium binding proteins may act much like local “switches”, 
operated through changes in local, perhaps unitary calcium flux that coordinate nanocourse-specific 
functions by adjusting the relative probability of a given switch sitting at some conformational state 
between OFF and ON. Moreover, in this way coincident increases in calcium flux could be triggered in 
two distant parts of the cell at the same time, to coordinate, for example, myocyte relaxation and 
associated gene expression regulation. This draws obvious parallels to mechanisms of conduction in 
single-walled carbon nanotubes, which behave as quantum wires that transmit charge carriers through 
discrete conduction channels, enabling memory, logic and parallel processing. Thus, by analogy, our 
observations point to the incredible signalling potential that may be afforded by modulating quantum 
calcium flux on the nanoscale, in support of network activities within cells with the capacity to permit 
stimulus-dependent orchestration of the full panoply of diverse cellular processes. Perhaps more 
importantly, this cellular intranet and its associated network activities are not hardwired, reconfiguring 
to deliver different outputs during phenotypic modulation on the path, for example, to cell 
proliferation. In a similar way the cell-wide web may provide the capacity for cell- and system-specific 
outputs, because nuclear envelope invaginations are a feature of many cell types [15–19], indicating 
that the cell-wide web and its constituent nuclear nanocourses may vary in nature between different 
cell types in order to meet the functional requirements of any given cell [11,149,188,232]. 
In conclusion, it is time for the field of cellular signalling to move away from casual reference to 
microdomains, nanodomains and nanospaces, because these are all meaningless adjustments in 
terminology in the context of cellular signalling. They simply indicate smaller size or increased 
resolution, and offer no true functional insight, with the possible exception of organelle-specific 
autoregulation. Moreover, given that estimates of the volume of cytoplasm demarcated by SR 
nanojunctions are of the order of picolitres [147,172], when considering cytoplasmic domains or spaces 
they are all inaccurate terms. In short, it is the dimensions of the nanojunction or nanotube that are 
critical to effective control of site-specific ion flux or exchange across the cell-wide web. So, when it 
comes to appropriate and informed use of terminology, nanojunction it is. 
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